Abstract
It is becoming increasingly acknowledged that tumorigenesis is not simply characterized by the accumulation of rapidly proliferating, genetically mutated cells. Microenvironmental biophysical factors like hypoxia and acidity dramatically condition cancer cells and act as selective forces for malignant cells, adapting through metabolic reprogramming towards aerobic glycolysis. Avoiding intracellular accumulation of lactic acid and protons, otherwise detrimental to cell survival is crucial for malignant cells to maintain cellular pH homeostasis. As a consequence of the upregulated expression and/or function of several pH-regulating systems, cancer cells display an alkaline intracellular pH (pHi) and an acidic extracellular pH (pHe). Among the pH-regulating proteins, proton pumps play an important role in both drug-resistance and metastatic spread, thus representing a suitable therapeutic target. Proton pump inhibitors (PPI) have been reported as cytotoxic drugs active against several human tumor cells and preclinical data have prompted the investigation of PPI as anticancer agents in humans. This review will update the current knowledge on the antitumor activities of PPI and their potential applications.
Keywords: Proton pump inhibitors, omeprazole, cancer therapy, tumor pH, V-ATPase, cell survival, aerobic glycolysis, cellular pH homeostasis, cytotoxic drugs, hypoxia
Current Pharmaceutical Design
Title: A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Volume: 18 Issue: 10
Author(s): Angelo De Milito, Maria Lucia Marino and Stefano Fais
Affiliation:
Keywords: Proton pump inhibitors, omeprazole, cancer therapy, tumor pH, V-ATPase, cell survival, aerobic glycolysis, cellular pH homeostasis, cytotoxic drugs, hypoxia
Abstract: It is becoming increasingly acknowledged that tumorigenesis is not simply characterized by the accumulation of rapidly proliferating, genetically mutated cells. Microenvironmental biophysical factors like hypoxia and acidity dramatically condition cancer cells and act as selective forces for malignant cells, adapting through metabolic reprogramming towards aerobic glycolysis. Avoiding intracellular accumulation of lactic acid and protons, otherwise detrimental to cell survival is crucial for malignant cells to maintain cellular pH homeostasis. As a consequence of the upregulated expression and/or function of several pH-regulating systems, cancer cells display an alkaline intracellular pH (pHi) and an acidic extracellular pH (pHe). Among the pH-regulating proteins, proton pumps play an important role in both drug-resistance and metastatic spread, thus representing a suitable therapeutic target. Proton pump inhibitors (PPI) have been reported as cytotoxic drugs active against several human tumor cells and preclinical data have prompted the investigation of PPI as anticancer agents in humans. This review will update the current knowledge on the antitumor activities of PPI and their potential applications.
Export Options
About this article
Cite this article as:
De Milito Angelo, Lucia Marino Maria and Fais Stefano, A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents, Current Pharmaceutical Design 2012; 18 (10) . https://dx.doi.org/10.2174/138161212799504911
DOI https://dx.doi.org/10.2174/138161212799504911 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Carbon Nanomaterials in Gene Delivery for Endogenous RNA Interference <i>In Vitro</i> and <i>In Vivo</i>
Current Pharmaceutical Design Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Current Pharmaceutical Design Caveats Regarding the Use of IL-10 and IL-10 Antagonist as Immunotherapeutic Factors
Letters in Drug Design & Discovery Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Medicinal Plants for the Prevention and Treatment of Bacterial Infections
Current Pharmaceutical Design Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine Disintegrins
Current Drug Targets - Cardiovascular & Hematological Disorders Recent Advances in the Treatment of Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery Chemical Synthesis, Characterisation and Biological Evaluation of Furanic- Estradiol Derivatives as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Medicinal Chemistry Antimicrobial Chitosan based Formulations with Impact on Different Biomedical Applications
Current Pharmaceutical Biotechnology Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice
Current Drug Delivery Stem Cells, Cancer, Liver, and Liver Cancer Stem Cells: Finding a Way Out of the Labyrinth...
Current Cancer Drug Targets Oncostatin M: Potential Implications for Malignancy and Metabolism
Current Pharmaceutical Design Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy MicroRNA-10b Induces Vascular Muscle Cell Proliferation Through Akt Pathway by Targeting TIP30
Current Vascular Pharmacology A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Tannic Acid Inhibits Proliferation, Migration, Invasion of Prostate Cancer and Modulates Drug Metabolizing and Antioxidant Enzymes
Anti-Cancer Agents in Medicinal Chemistry Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Anti-Cancer Agents in Medicinal Chemistry